Blackstone and Carlyle Group are reportedly keen to pair up and bid for Sandoz which could be valued at US$25 billion. This interest in the takeover of Sandoz was sparked when the company revealed that they were carrying out a strategic review of the unit due to reduced Sandoz product sales in the US. This is due to conclude at the end of 2022 [1].

This news comes following a recent announcement that the Swiss Social Democratic party are also interested in the purchase and nationalization of the generics unit [2]. Novartis has also hinted that they are aware of other interest in the purchase of Sandoz.

Should Novartis choose to separate from Sandoz, it will follow in the footsteps of Merck’s Organon, a global healthcare company formed through a spinoff from Merck, which has a primary focus of improving the health of women throughout their lives [1].

Related article
Collaborations to commercialize oncology biosimilars

References
1. GaBI Online - Generics and Biosimilars Initiative. Spinoff updates Merck’s Organon and Novartis’ Sandoz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from: www.gabionline.net/pharma-news/spinoff-updates-merck-s-organon-and-novartis-sandoz
2. GaBI Online - Generics and Biosimilars Initiative. Swiss Social Democrat’s for nationalization of Sandoz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from: www.gabionline.net/pharma-news/swiss-social-democrat-s-for-nationalization-of-sandoz

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.